Results 71 to 80 of about 18,145 (196)
MedComm, Volume 7, Issue 7, July 2026.Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu +7 more
wiley +1 more source
, 2013 Purpose: To compare the corneal endothelial changes after injection of a single-dose intravitreal bevacizumab or intravitreal ranibizumab. Material and Method: In this retrospective study, we evaluated 27 eyes of 27 patients with either diabetic ...
Tansu Gönen +2 more
core +1 more source
Choroidal Osteoma and Secondary Choroidal Neovascularization Treated with Ranibizumab [PDF]
, 2017 A 47-year-old female patient presented with a complaint of decreased vision in the right eye. Her visual acuity was 0.16 in the right eye and 1.0 in the left eye.
Bayar, Sezin Akca +5 more
core +1 more source
Ranibizumab and its use in the treatment of diabetic macular edema
, 2018 The dissertation concerns the use of the vascular endothelian growth factor inhibitor medication known as Ranibizumab in the treatment of patients affected by diabetic macular edema, while comparing its effectiveness with other contemporary forms of ...
Tieger, Leonardo
core
Journal of Diabetes Investigation, Volume 17, Issue 7, Page 1120-1131, July 2026.Combining oral sodium‐glucose cotransporter 2 inhibitors with reduced intravitreal injections of anti‐vascular endothelial growth factor showed potential efficacy for mild diabetic macular edema. ABSTRACT Aims To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular
Yoko Takatsuna +6 more
wiley +1 more source
Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context
BMC Ophthalmology, 2018 Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid +9 more
doaj +1 more source
Current perspectives on ranibizumab
, 2015 Vaidehi S Dedania,1 Sophie J Bakri21Department of Ophthalmology, Albany Medical Center, Lions Eye Institute, Albany, NY, USA; 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, USABackground: This review summarizes the Phase III studies addressing
Bakri SJ, Dedania VS
core
Dapagliflozin prevents methylglyoxal‐induced retinal cell death in ARPE‐19 cells
FEBS Open Bio, Volume 16, Issue 6, Page 1150-1165, June 2026.Diabetic macular oedema is a diabetes complication of the eye, which may lead to permanent blindness. ARPE‐19 are human retinal cells used to study retinal diseases and potential therapeutics. Methylglyoxal is a compound increased in uncontrolled diabetes due to elevated blood glucose.
Naina Trivedi +7 more
wiley +1 more source
Results of Intravitreal Ranibizumab Treatment for Exudative Age-Related Macular Degeneration
, 2012 Pur po se: To evaluate the efficacy and safety of intravitreal ranibizumab injection for exudative age-related macular degeneration. Ma te ri al and Met hod: In this study, we included forty-eight eyes of 43 age-related macular degeneration patients ...
Ali Hakan Durukan +4 more
core +1 more source